Immatics Biotechnologies GmbH has received €22 million from its venture capital investors – the final tranche in a Series D round that will enable it to complete a Phase 3 trial of a cancer vaccine for renal cell carcinoma, a type of kidney cancer.
A Phase 3 trial of a new combination therapy for advanced melanoma has reached its primary endpoint of progression-free survival, the Roche Group announced. The trial was investigating Zelboraf and the experimental drug cobimetinib versus Zelboraf alone.
The Board of Shire Plc has responded favourably to a revised takeover proposal from AbbVie Inc which values Shire at £53.20 per share, up from £51.15 per share earlier. The board is in detailed discussions with the US company about other terms of the proposed deal.
Salix Pharmaceuticals Inc is the latest company to take advantage of low corporate tax rates in Ireland through its planned merger with the Irish subsidiary of Cosmo Pharmaceuticals SpA of Italy. The transaction is expected to close in the fourth quarter.
Advanced Accelerator Applications SA, a French manufacturer of nuclear medicine products, increased its sales of diagnostic products in 2013 while advancing its lead radiopharmaceutical, Lutathera, for patients with neuroendocrine tumours.
A UK-based drug services company, Ergomed Plc, is to be admitted to the Alternative Investment Market of the London Stock Exchange following a fundraising of £11 million. Shares in the company are expected to start trading on 15 July.
ArGEN-X NV, which is developing antibody therapeutics for cancer and autoimmune diseases, has raised €40 million in an initial public offering on the Euronext stock exchange in Brussels. If over-allotment options are exercised in full, total proceeds will rise to €44 million.
Shire Plc has urged its shareholders not to act in response to a new cash and share takeover proposal from AbbVie Inc that values the company at about £51.15 per share, up by 11% from £46.26 per share earlier. The proposal is AbbVie’s fourth for the Dublin-based company.
Life Sciences Partners (LSP) BV of the Netherlands is leading a €4.4 million Series A financing round for privately-held Mint Solutions Holding BV which has developed technology for verifying that drugs administered in a hospital correctly match their prescriptions.
A division of the US National Institutes of Health is to support the creation of a new database that will enable the study of the interaction of more than 1,400 Food and Drug Administration-approved drugs and drug-like compounds with more than 30 epigenetic enzymes.